Assessments und Outcome-Parameter bei axialer Spondyloarthritis

Zusammenfassung

Die standardisierte Erfassung der klinischen Manifestation und Patienten-berichteter Endpunkte (heute international gebräuchlich Outcomes) von Patienten mit axialer Spondyloarthritis (axSpA) ist notwendig, um die Erkrankung hinsichtlich Ausmaß und Aktivität der Erkrankung so objektiv wie möglich abbilden zu können und damit die Grundlage für klinische Entscheidungen zu schaffen. Die standardisierte Erfassung bezieht sich auf Domänen wie Krankheitsaktivität, Lebensqualität, Funktions- und Erwerbsfähigkeit, aber auch auf einzelne Aspekte wie Schmerzen, Arthritis und Enthesitis. Sowohl die Domänen als auch die Einzelaspekte werden überwiegend als direkt vom Patienten berichtete Endpunkte mittels eines Selbstauskunftsbogens erhoben (patient reported outcomes (PRO)). Ausnahme bildet die Erfassung der entzündlichen Beteiligung von Gelenken und Sehnenansätzen und die körperliche Untersuchung der Wirbelsäulenmobilität. In interventionellen Studien werden Status- oder Response-Kriterien eingesetzt, um die Veränderung, oft ausgedrückt als20 oder 40%ige Verbesserung, quantitativ erfassen zu können. Die Instrumente sind in den 90er Jahren in Bath und in den letzten 20 Jahren von ASAS (Assessments in Axial Spondlyoarthritis International Society) entwickelt worden.

Abstract

A standardised assessment of outcomes in patients with axial spondyloarthritis (axSpA) is necessary in order to assess clinical manifestation, disease activity and severity as objectively as possible. The standardised assessment refers to domains such as disease activity, quality of life, functional capacity and employment, but also to individual aspects such as pain, arthritis and enthesitis. The domains as well as the individual aspects are mainly collected as patient-reported outcomes (PROs), with the exception of the clinical examination of joints, entheses and the spine. In clinical trials, status or response criteria are used to quantify the change, often referred to as a 20% or 40% improvement. The instruments were developed in Bath in the 1990s and by ASAS (Assessments in Axial Spondyloarthritis International Society) in the past 20 years.

Schlüsselwörter

spondyloarthritis - outcome - assessment

Key words

spondyloarthritis - outcome - assessment

• Literatur

• 1 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390: 73-84
• 2 Anderson JJ, Baron G, van der Heijde D. et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-1886
• 3 Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A. et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-132
• 4 Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-691
• 5 Maksymowych WP, Mallon C, Morrow S. et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 948-953
• 6 Mease PJ, Van den Bosch F, Sieper J. et al. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol 2017; 44: 599-608
• 7 Garrett S, Jenkinson T, Kennedy LG. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2291
• 8 Lukas C, Landewé R, Sieper J. et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24
• 9 Braun J, Brandt J, Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193
• 10 Essers I, Boonen A, Busch M. et al. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Rheumatology (Oxford) 2016; 55: 2014-2022
• 11 Santos-Faria D, Dougados M, Gossec L. et al. Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. Rheumatol Int 2019; 39: 141-146
• 12 Rudwaleit M, Listing J, Brandt J. et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-670
• 13 Machado P, Landewé R, Lie E. et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70: 47-53
• 14 Molto A, Gossec L, Meghnathi B. et al. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis 2018; 77: 124-127
• 15 Landewé R, Dougados M, Mielants H. et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009; 68: 863-867
• 16 Ramiro S, van Tubergen A, Stolwijk C. et al. Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. Ann Rheum Dis 2015; 74: 1218-1224
• 17 Sieper J, Rudwaleit M, Baraliakos X. et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 (Suppl 2): 1-44
• 18 Deutsche Gesellschaft für Rheumatologie e.V. (DGRh). S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen (09.11.2018). Im Internet: https://www.awmf.org/leitlinien/detail/ll/060-003.html Stand 16.09.2019
• 19 Jenkinson TR, Mallorie PA, Whitelock HC. et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-1698
• 20 Calin A, Garrett S, Whitelock H. et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-2285
• 21 Ruof J, Sangha O, Stucki G. Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 1999; 58: 218-225
• 22 Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
• 23 Kiltz U, van der Heijde D, Boonen A. et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015; 74: 830-835
• 24 Doward LC, Spoorenberg A, Cook SA. et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-26
• 25 Hurst NP, Kind P, Ruta D. et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-559
• 26 Reilly MC, Gooch KL, Wong RL. et al. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford) 2010; 49: 812-819
• 27 Shim J, Jones GT, Pathan EMI. et al. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis. Ann Rheum Dis 2018; 77: 1578-1584
• 28 Sieper J, Lenaerts J, Wollenhaupt J. et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014; 73: 101-107
• 29 Landewé R, Sieper J, Mease P. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 2018; 392: 134-144